|Bid||2.57 x 400|
|Ask||2.64 x 2000|
|Day's Range||2.56 - 2.67|
|52 Week Range||0.57 - 4.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Michael Bailey took the helm as AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO and grew market cap to $363.25M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is wrapping up the refinancing of its existing debt facility with Hercules and affiliates: one with a $20 million tag. The terms of the refinancing will provide a roughly $12.1 million in cash flow over the course of this year and next when against the previous loan, and the AVEO corporate team is rejoicing that this will extend the runway into 2019. Proceeds of the new facility will be used to retire the Company’s existing $20.0 million of secured debt with Hercules.
Investors in AVEO Pharmaceuticals (AVEO) need to pay close attention to the stock based on moves in the options market lately.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced updates on clinical development for FOTIVDA® (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway. Enrollment Complete in Phase 2 Portion of Phase 1/2 TiNivo Trial in Advanced RCC. AVEO announced today that enrollment of 21 patients is now complete, with one patient remaining in screening, in the Phase 2 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb’s OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced RCC.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today expanded its executive team by naming Nikhil Mehta, Ph.D. as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience in the biotechnology and pharmaceutical industries, having played a key role in the development and approval of important therapeutic products in the areas of oncology and orphan disease.
AVEO Pharmaceuticals Inc (NASDAQ:AVEO), a USD$362.06M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the third quarter ended September 30, 2017 and provided a business update. Notably, with the European approval of tivozanib (FOTIVDA®) in advanced RCC, we have transitioned from a development stage company to one with a commercially approved product, a watershed achievement for any emerging life sciences company,” said Michael Bailey, president and chief executive officer of AVEO. “In addition, TIVO-3, our U.S. registration study, successfully passed the interim futility analysis with no changes to study protocol.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 22 cents. Losses, adjusted for non-recurring costs, came to 2 cents per share. The cancer drug company posted revenue ...
AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives AVEO Pharmaceuticals, Inc. a score of 7. Our analysis is based on comparing AVEO Pharmaceuticals, Inc. with the following peers – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., GTx, Inc., Bristol-Myers Squibb Company, Merrimack Pharmaceuticals, Inc., Amgen Inc. and Eli Lilly and Company (BIIB-US, REGN-US, ARQL-US, GTXI-US, ... Read more (Read more...)